Follow-up of two adult brothers with homozygous CEP57 pathogenic variants expands the phenotype of Mosaic Variegated Aneuploidy Syndrome.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 16 03 2020
revised: 15 07 2020
accepted: 20 08 2020
pubmed: 31 8 2020
medline: 1 5 2021
entrez: 31 8 2020
Statut: ppublish

Résumé

Mosaic Variegated Aneuploidy Syndrome (MVA) is a rare autosomal recessive disorder characterized by mosaic aneuploidies involving multiple chromosomes and tissues. Affected individuals typically present with severe intrauterine and postnatal growth retardation, microcephaly, facial dysmorphism, developmental delay and predisposition to cancer and epilepsy. Three genes, BUB1B, CEP57 and TRIP13, are involved in this syndrome. Only 7 patients carrying pathogenic variants in CEP57 are reported to date. Here we report two adult brothers born to Moroccan related parents, who presented with intrauterine and postnatal growth retardation, microcephaly, facial dysmorphism, learning disabilities, skeletal anomalies with thumb hypoplasia and dental abnormalities. Both brothers have mosaic variegated aneuploidies on blood karyotype. A previously reported homozygous 11 bp duplication was identified in CEP57 in the two brothers. We propose that a FoSTeS (Fork Stalling and Template Switching) mechanism could be involved in the occurrence of this duplication. This report expands the phenotypical spectrum associated with CEP57 and highlights the interest of blood karyotype in patients presenting with short stature and microcephaly.

Identifiants

pubmed: 32861809
pii: S1769-7212(20)30111-7
doi: 10.1016/j.ejmg.2020.104044
pii:
doi:

Substances chimiques

CEP57 protein, human 0
Microtubule-Associated Proteins 0
Nuclear Proteins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104044

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Tania Dery (T)

Service de Génétique, Hospices Civils de Lyon, Bron, France.

Nicolas Chatron (N)

Service de Génétique, Hospices Civils de Lyon, Bron, France; Equipe GENDEV, CRNL, INSERM U1028 CNRS UMR5292 Université Claude Bernard Lyon 1, Lyon, France.

Amerh Alqahtani (A)

Service de Génétique, Hospices Civils de Lyon, Bron, France.

Michel Pugeat (M)

Service d'Endocrinologie, Hospices Civils de Lyon, Bron, France.

Marianne Till (M)

Service de Génétique, Hospices Civils de Lyon, Bron, France.

Patrick Edery (P)

Service de Génétique, Hospices Civils de Lyon, Bron, France; Equipe GENDEV, CRNL, INSERM U1028 CNRS UMR5292 Université Claude Bernard Lyon 1, Lyon, France.

Damien Sanlaville (D)

Service de Génétique, Hospices Civils de Lyon, Bron, France; Equipe GENDEV, CRNL, INSERM U1028 CNRS UMR5292 Université Claude Bernard Lyon 1, Lyon, France; Institut NeuroMyoGène, CNRS UMR 5310 - INSERM U1217, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Caroline Schluth-Bolard (C)

Service de Génétique, Hospices Civils de Lyon, Bron, France; Equipe GENDEV, CRNL, INSERM U1028 CNRS UMR5292 Université Claude Bernard Lyon 1, Lyon, France; Institut NeuroMyoGène, CNRS UMR 5310 - INSERM U1217, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Marc Nicolino (M)

Service d'Endocrinologie Pédiatrique, Hospices Civils de Lyon, Bron, France.

Gaetan Lesca (G)

Service de Génétique, Hospices Civils de Lyon, Bron, France; Equipe GENDEV, CRNL, INSERM U1028 CNRS UMR5292 Université Claude Bernard Lyon 1, Lyon, France; Institut NeuroMyoGène, CNRS UMR 5310 - INSERM U1217, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Audrey Putoux (A)

Service de Génétique, Hospices Civils de Lyon, Bron, France; Equipe GENDEV, CRNL, INSERM U1028 CNRS UMR5292 Université Claude Bernard Lyon 1, Lyon, France. Electronic address: audrey.putoux@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH